Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report published on Tuesday. The firm issued a hold rating on the medical research company’s stock.

Other research analysts have also recently issued research reports about the stock. EF Hutton Acquisition Co. I upgraded shares of Cytosorbents to a strong-buy rating in a report on Monday, July 29th. HC Wainwright restated a neutral rating and issued a $1.00 target price on shares of Cytosorbents in a report on Tuesday, May 7th. Finally, B. Riley restated a buy rating and issued a $3.00 target price on shares of Cytosorbents in a report on Wednesday, May 15th.

Cytosorbents Stock Up 1.0 %

NASDAQ CTSO traded up $0.01 on Tuesday, hitting $1.05. 18,133 shares of the stock were exchanged, compared to its average volume of 131,662. The company has a quick ratio of 1.21, a current ratio of 1.49 and a debt-to-equity ratio of 0.10. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $3.09. The company has a market cap of $57.02 million, a PE ratio of -1.78 and a beta of 0.57. The company has a 50-day moving average price of $0.95 and a 200-day moving average price of $0.94.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). Cytosorbents had a negative net margin of 75.07% and a negative return on equity of 129.89%. The company had revenue of $9.79 million during the quarter, compared to analysts’ expectations of $9.78 million. During the same quarter in the previous year, the business posted ($0.17) EPS. Sell-side analysts anticipate that Cytosorbents will post -0.36 EPS for the current fiscal year.

Institutional Trading of Cytosorbents

A number of large investors have recently bought and sold shares of CTSO. Raymond James & Associates acquired a new stake in Cytosorbents during the 4th quarter worth $56,000. Sargent Investment Group LLC boosted its stake in Cytosorbents by 4.1% during the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock worth $1,453,000 after purchasing an additional 51,699 shares during the period. Skylands Capital LLC boosted its stake in Cytosorbents by 10.5% during the 4th quarter. Skylands Capital LLC now owns 3,254,213 shares of the medical research company’s stock worth $3,612,000 after purchasing an additional 309,543 shares during the period. Neuberger Berman Group LLC lifted its stake in shares of Cytosorbents by 19.9% in the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after acquiring an additional 299,103 shares during the period. Finally, Avenir Corp lifted its stake in shares of Cytosorbents by 12.3% in the 4th quarter. Avenir Corp now owns 3,051,402 shares of the medical research company’s stock worth $3,387,000 after acquiring an additional 334,005 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.